Acetylsalicylic acid and vorapaxar are less active, while 4-methylcatechol is more active, in type 1 diabetic patients compared to healthy controls
Authors' conclusion
Conclusively, 4-methylcatechol seems to be a prototypical antiplatelet compound with a strong effect even in diabetic patients.
Study context
- Population
- Adults with T1D and age-matched healthy controls; responses to 7 platelet aggregation inducers, ASA, ticagrelor, vorapaxar and 4-methylcatechol assessed ex vivo
- Participants
- 50 vs 50
- Comparison
- Platelet responses to aggregation inducers and antiplatelet drugs in T1D vs healthy controls
- T1Dn = 50
- Controlsn = 50reference
- Outcome
- Platelet aggregation and antiplatelet drug effects
Methodological detailsex vivo, age-matched controls
- Ex vivo
- Age-matched controls
Main finding
As reported in the abstract
- T1D: lower aggregation reaction to 3 inducers vs controls
- T1D more resistant to the effect of ASA and vorapaxar than controls
- Ticagrelor tended to be less active in T1D
- 4-methylcatechol equally or even more potent in T1D than in healthy controls
Observational data: associations, not effects.
Further findings
Plasma glucose >7 mM
- Plasma glucose >7 mM associated with lower platelet aggregation responses to 4 inducers
- Effect of 4-methylcatechol, unlike ASA, not strongly influenced by glycemia
Subanalyses excluding hypertensive patients and more frequently administered drugs
- Did not substantially modify the results
Original publication
Acetylsalicylic acid and vorapaxar are less active, while 4-methylcatechol is more active, in type 1 diabetic patients compared to healthy controls. Cardiovasc Diabetol. Published 7 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →